Is Calumet Specialty Products Partners (CLMT) overvalued? · rev $4.19B
Calumet Specialty Products Partners (CLMT) is a specialty chemicals company listed on NASDAQ.
This page asks whether Calumet Specialty Products Partners (CLMT) looks expensive on cached numbers — not a short thesis.
Latest reported CLMT revenue for 2024-12-31 was $4.19B. Net income was -$222.0M. Revenue was up 0.2% from 2023-12-31 to 2024-12-31. CLMT currently screens at market cap $2.89B.
CLMT currently screens at market cap $2.89B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CLMT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CLMT stock page for the full model, not this heading.
Not investment advice.